Clinical Trial Update: Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy [NA]

View source ↗

Summary

A clinical trial is evaluating contrast-enhanced spectral mammography (CESM) as an early biomarker to assess tumor response and predict pathologic complete resp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Breast Cancer | NA | Status: RECRUITING